Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Pridgen WilliamOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,917Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Thomas John COwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,167Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Whitley Richard JamesOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,000Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Keefer David ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,709Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Burch Richard AlanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,917Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:De La Rosa AbelOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,959Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Walsh AngelaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,618Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Grosswald RalphOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:62,568Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Gendreau Roger MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:88,085Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Duncan Gregory ScottOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:138,835Price:--
Filings by filing date
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Pridgen WilliamOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,917Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Thomas John COwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,167Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Whitley Richard JamesOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,000Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Keefer David ROwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,709Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Burch Richard AlanOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,917Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:De La Rosa AbelOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,959Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Walsh AngelaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:63,618Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Grosswald RalphOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:62,568Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Gendreau Roger MichaelOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:88,085Price:--
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Duncan Gregory ScottOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:138,835Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 44 Milton Avenue ALPHARETTA GA 30009 |
Tel: | N/A |
Website: | https://www.virios.com |
IR: | See website |
Key People | ||
Gregory Scott Duncan Chairman of the Board, Chief Executive Officer | Angela Walsh Senior Vice President - Finance | Ralph Grosswald Senior Vice President of Operations | R. Michael Gendreau Chief Medical Officer |
Business Overview |
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state. |
Financial Overview |
For the fiscal year ended 31 December 2023, Virios Therapeutics Inc revenues was not reported. Net loss decreased 57% to $5.3M. Lower net loss reflects Research and development decrease of 79% to $1.7M (expense), General and administrative decrease of 12% to $3.7M (expense), Other income increase from $0K to $151K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$0.28. |
Employees: | 4 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$5.45M as of Dec 31, 2023 |
Net annual income (TTM): | -$5.30M as of Dec 31, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 19,257,937 as of Jan 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |